Alex Sanfeliu

Global Head of the Pharmaceutical Technologies Business Unit: hospital products, wordwide scope via affiliates and partners, plus CDMO for injectables. Therapeutical areas: Anti-infectives, Critical Care, CNS, Cardiovascular… Full global P&L ownership. Founded in 1929 in Barcelona, Reig Jofré is a pharmaceutical company listed on the Spanish Stock Exchange, dedicated to the research, development, manufacturing, and marketing of pharmaceutical products and food supplements. The company is structured around three business areas: - Pharmaceutical Technologies specialized in the development, manufacturing and commercialisation of hospital products: sterile and lyophilized injectables, as well as antibiotics. - Specialty Pharmacare focused on products mainly in the areas of dermatology and osteoarticular. - Consumer Healthcare with food supplements and other OTC products. REIG JOFRE has more than 1.400 employees, 4 development and production centres in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), subsidiaries in 8 countries, and +100 business partners in more than 70 countries.

Gamification for medical education. Company founded in 2017 by two ophthalmologists, Dr. Rodolfo Aburto and Dr. Javier Sambricio, who, seeing the need to transform medical education, and observing how technology opened up so many new avenues, decided to invest and develop medical courses in a videogame format. This changed the paradigm of medical education and allowed learning contents to be adapted to the leisure moments of doctors. They have extensive experience in the design of videogames with educational content and have been the first to make videogames for healthcare professionals.

Led a cross-functional team at Endogena Therapeutics to deep dive on the commercial potencial of EA-2353 for Retinitis Pigmentosa. Developed a 10-year worldwide sales forecast, with a focus on key markets including the US, EU, and the Rest of the World. Dissected complex market dynamics and projected future sales. Provided strategic insights to Endogena Therapeutics to shape the commercial strategy for this promising RP asset. Endogena therapeutics is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Their approach has the potential of a paradigm shift to treat degenerative conditions related to aging and genetic disorders.

Full P&L accountability with consistent growth in sales and profitability despite COVID. Markets: Specialty, Hospital, Biologic, Rare Diseases, Gene Therapy. Successfully launched 2 brands: a new generation a-vegf for wAMD, and the first gene therapy in retina, for rase diseases. Recognized internally and externally for best-in-class launch preparation, customer advocacy, and omnichannel engagement. Built and led a team of 80 including direct Marketing and Sales, and indirect cross-functional teams with focus on high performance, collaboration, and talent development. Member of Spanish Pharma Executive Committee and the Global Ophthalmology Leadership Team. Selected as European representative for global project to optimize governance and decision-making. Led an integrated plan to transform wet Age-related Macular Degeneration management in Spain, including public affairs, awareness, early medical engagement, and patient journey acceleration programs. Resulted in double-digit market growth and improved patient outcomes. Pioneered the transformation of the company´s value and digital proposition to Hospitals/Regions based on: - new commercial models (e.g. yearly treatment cost, subscription, risk sharing...) - innovative value-added projects (e.g. co-development of new AI algorithm to screen Diabetic Retinopathy, introduction in Spain of 1st video game to monitor patients vision from home...) - inclusion of models and projects in offers/tenders combined with omnichannel comms plan, covering both public and private markets Ranked #1 by IQVIA and Merco as most innovative and best reputation company in Ophthalmology in Spain.

Secretary to the Global Commercial Leadership Team, contributing and shaping the strategic commercial agenda. Responsible for Operations and Planning, lead strategic projects including: new operating model for the global/regional/local marketing organization; 1st cross-divisional launch excellence summit for top 100 executives; healthcare professional benchmark on new medical engagement strategies and pilot of new digital promotional channels.

South-East Spain, team of 13 reps, annual sales $35M, 5 brands Diabetes-Hypertension-Pain, Physician-Pharmacy. Team achieved market leadership in 8 months.

Annual sales $100M, +40 products in diverse disease areas. Successful turn-around exceeding sales & profitability targets through transformation of the commercial model to adapt to new market environment and regulation: new multi-channel plan for pharmacies and wholesalers; pricing and commercial strategy for Voltaren Emulgel after delisting; 2 licensing deals. Selected for Leadership Discovery Program, Novartis 1 year program for European High Potentials.

Lead Diabetes cross-functional team, 6 brands (2 co-marketers) reached $94M annual sales, best-in-class launch resulting in market leadership and top selling product at Novartis Pharma Spain and Novartis Diabetes World Wide.

Secretary to the Spanish Executive Committee. 2009-2011: Lead a project team of 4 to identify, promote and track group synergies, reporting to Country President, exceeding +1% group revenue from cross-divisional initiatives.

The Venture Gang was a start-up factory founded in 2014 by a group of investors working on different industries (FMCG, Healthcare, Consulting, Banking...). Closed in 2021.

Talentier was the 1st headhunting marketplace, nethunting. Talentier was born, within the factory The Venture Gang, to efficiently match top talent with exciting job opportunities through technology and a specialized network.

Mobile marketing project for Vodafone. Paper to discuss Energy sector strategy for Iberdrola, top Spanish Energy company, acquiring Scottish Power, a UK competitor.

Reviewed Business Planning/Forecasting and Consolidation process at Etam, top Fashion Retail International Company

Design and implementation of new strategic planning and rolling forecast for Universal Pictures world wide. One year on-site international roll-out of the project based in Madrid, Rome, Amsterdam, Stockholm, Seoul, São Paulo. Streamline of the British Broadcasting Corp. finance and forecasting function.

Passed with Distinction

Understanding cost-effectiveness helps you to use a brand’s health economic strengths in a customer-facing role – Understanding the payer’s perspective enables organisations to produce better health-economic evidence and integrate this perspective into external communications – Understanding the contribution of health economics to a brand’s success from early clinical development up to post-launch enables you to contribute to evidence generation wherever you work in a product’s lifecycle.

Learn the different payer archetype systems that offer useful patterns in payer decision making and an insightful structure in Europe’s highly fragmented payer landscape – Grasp the structure and know the key stakeholders of the major European healthcare systems – Understand the contribution of other functions in the process of gaining optimal access.

Learn the evidence-based concepts, models and techniques that work best to forecast the sales of pharmaceuticals – Know how to build Market Access into your forecasts – Learn to distinguish reliable from bad forecasts and how to forecast cost-effectively – Get practice with an Excel-based forecasting tool that integrates all the techniques taught.